CoChat

A 20-Year Longitudinal Observational Study of Somatic Antidepressant Treatment Effectiveness

Leon, Andrew C., Solomon, David A., Mueller, Timothy I., Endicott, Jean, Rice, John P., Maser, Jack D., Coryell, William, Keller, Martin B. · 2003 · American Journal of Psychiatry
Cited by 55

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This observational study examined the effectiveness of somatic antidepressant treatments as administered in the community. METHOD: The study group consisted of 285 subjects with an intake diagnosis of major depressive disorder who had entered the National Institute of Mental Health Collaborative Depression Study as early as 1978, had at least one additional affective episode, and had been followed for up to 20 years, as recently as 1999. The characteristics that distinguished subjects receiving various levels of somatic antidepressant treatment were accounted for in what was called a propensity for treatment intensity model. The effectiveness of somatic antidepressant treatment during major affective episodes was then examined. RESULTS: Those who received higher levels of antidepressant treatment tended to have more prior episodes, more severe depressive symptoms, and more intensive somatic therapy during prior episodes and prior well intervals than those who received lower levels. Treatment effectiveness analyses that were stratified by propensity for treatment intensity demonstrated that those who received higher levels of antidepressant treatment were significantly more likely to recover from affective episodes. In contrast, those treated with lower levels were no more likely to recover than those who did not receive somatic treatment. CONCLUSIONS: Despite the indications of more severe depressive illness, those who received higher levels of somatic antidepressant treatment were more likely to recover from recurrent affective episodes. Results from this observational study extend the generalizability of reports from randomized clinical trials of antidepressants to a wider, more representative group of individuals who suffer from major depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.160.4.727

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD: Meta-analysis of randomised controlled trials of fluoxetine v placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000; 176:421-428 · DOI · Paper page
  2. Claghorn JL, Earl CQ, Walczak DD, Stoner KA, Wong LF, Kanter D, Houser VP: Fluvoxamine maleate in the treatment of major depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996; 16:113-120 · DOI · Paper page
  3. Cohn JB, Crowder JE, Wilcox CS, Ryan PJ: A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol Bull 1990; 26:185-189
  4. Feighner JP, Overo K: Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999; 60:824-830 · DOI · Paper page
  5. Lydiard RB, Stahl SM, Hertzman M, Harrison WM: A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997; 58:484-491 · DOI · Paper page
  6. Mendels J, Kiev A, Fabre LF: Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety 1999; 9:54-60 · DOI
  7. Partonen T, Sihvo S, Lonnqvist JK: Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry 1996; 57:572-575 · DOI · Paper page
  8. Rosenbaum P, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55 · DOI · Paper page
  9. Rosenbaum PR, Rubin DB: Reducing bias in observational studies using subclassification on the propensity score. J Am Statistical Assoc 1984; 79:516-524 · DOI · Paper page
  10. Rubin DB, Rosenbaum PR: Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Statistician 1985; 39:33-38 · doi:10.1080/00031305.1985.10479383 · Paper page
  11. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-763 · DOI · Paper page
  12. Rosenbaum PR: Discussing hidden bias in observational studies. Ann Intern Med 1991; 115:901-905 · DOI · Paper page
  13. Katz MM, Klerman GL: Introduction: overview of the clinical studies program. Am J Psychiatry 1979; 136:49-51 · DOI · Paper page
  14. Endicott J, Spitzer RL: A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978; 35:837-844 · DOI · Paper page
  15. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35:773-782 · DOI · Paper page
  16. Keller MB: Undertreatment of major depression. Psychopharmacol Bull 1988; 24:75-80
  17. Leon AC, Mueller TI, Solomon DA, Keller MB: A dynamic adaptation of the propensity score adjustment for effectiveness analyses of ordinal doses of treatment. Stat Med 2001; 20:1487-1498 · DOI
  18. Hedeker D, Gibbons RD: A random-effects ordinal regression model for multilevel analysis. Biometrics 1994; 50:933-944 · DOI · Paper page
  19. Hedeker D, Siddiqui O, Hu FB: Random-effects regression analysis of correlated grouped-time survival data. Stat Methods Med Res 2000; 9:161-179 · DOI
  20. Endicott J, Cohen J, Nee J, Fleiss JL, Serantakos: Hamilton Depression Rating Scale: extracted from regular and change versions of the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1981; 38:98-103 · DOI · Paper page
  21. Klerman GL: Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. Psychopharmacol Bull 1986; 22:25-29

Cited by

See all 55

Metadata

Authors
Leon, A. C., Solomon, D. A., Mueller, T. I., Endicott, J., Rice, J. P., Maser, J. D., Coryell, W., & Keller, M. B.
Venue
American Journal of Psychiatry
Published
2003-04-01
Volume
160
Issue
4
Pages
727-733
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2118620879
Cited by
55
References
5
FWCI
3.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.